View all the latest information in lymphoma and CLL, arranged by therapeutic class and intervention. Listed below are recently updated therapeutic classes.
Alexander study: CD19/22 dual targeting CAR T-cell therapy with pembrolizumab in R/R DLBCL
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Lymphoma Hub was delighted to...
ZUMA-1 | Should age limit the use of axicabtagene ciloleucel?
Results from a post-hoc analysis of the two-year results of ZUMA-1, by age (
< 65 vs ≥ 65 years).
KEYNOTE-204: Pembrolizumab versus brentuximab vedotin R/R classic Hodgkin lymphoma
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Lymphoma Hub was pleased to speak to John...
Nivolumab plus AVD as first-line treatment for high-risk classic Hodgkin lymphoma
Paul J. Bröckelmann and colleagues conducted the open-label, multicenter, randomized, phase II NIVAHL study...
FDA grants CLR 131 fast track designation for the treatment of patients with lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia
On May 26, 2020, CLR 131, a radiotherapeutic phospholipid drug...
FDA grants CLR 131 Orphan Drug designation in lymphoplasmacytic lymphoma
On the 6th January 2020, CLR 131, an investigational small-molecule radio-therapeutic, was granted Orphan Drug Designation by...
Positive interim results announced for TRPH-222 in patients with NHL
On May 18, 2020, positive interim results were announced from the multi-center, open-label, phase I study of TRPH-222...
(177)Lu lilotomab satetraxetan receives positive opinion for orphan drug designation from EMA for MZL
On May 14, 2020, (177)Lu lilotomab satetraxetan received a positive opinion from the European...
CAR T-cell therapy
Chemokine receptor antagonists
(177)Lu lilotomab satetraxetan
Nuclear export inhibitors
Nuclear receptor agonists